Global Automated Nucleic Acid Extraction Devices Market – Industry Trends and Forecast to 2030

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Free Sample Report Free Sample Report Inquire Before Buying Inquire Before Buy Now Buy Now

Global Automated Nucleic Acid Extraction Devices Market – Industry Trends and Forecast to 2030

  • Medical Devices
  • Jan 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Circumvent the Tariff challenges with an agile supply chain Consulting

Supply Chain Ecosystem Analysis now part of DBMR Reports

Global Automated Nucleic Acid Extraction Devices Market

Market Size in USD Billion

CAGR :  % Diagram

Bar chart comparing the Global Automated Nucleic Acid Extraction Devices Market size in 2022 - 4.70 and 2030 - 11.15, highlighting the projected market growth. USD 4.70 Billion USD 11.15 Billion 2022 2030
Diagram Forecast Period
2023 –2030
Diagram Market Size (Base Year)
USD 4.70 Billion
Diagram Market Size (Forecast Year)
USD 11.15 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • QIAGEN
  • F. Hoffmann-La Roche Ltd
  • Analytik Jena GmbH+Co. KG
  • Thermo Fisher Scientific Inc.
  • AccuBioMed Co.Ltd.

Global Automated Nucleic Acid Extraction Devices Market, By Type (Instruments, Kits and Consumables), Product (Fully Automated, Semi-Automated), End User (Hospitals, Diagnostic Centers, Forensic Laboratories, Pharmaceutical and Biotechnology Companies, Academic Research Institutes) – Industry Trends and Forecast to 2030. 

Automated Nucleic Acid Extraction Devices Market

Automated Nucleic Acid Extraction Devices Market Analysis and Size

According to Data Bridge Market Research, the automated nucleic acid extraction devices market is expected to grow significantly in developed economies during the forecast period of 2023-2030 due to factors such as increasing adoption of superior technology for faster and better results, increasing demand for new extraction techniques, technological advancement in analytical instruments and laboratory automation, and other factors that are propelling the market forward. Furthermore, the increasing number of R&D activities will create new opportunities for the automated nucleic acid extraction devices market during the forecast period of 2023-2030.

Data Bridge Market Research analyses that the automated nucleic acid extraction devices market which is USD 4.7 billion in 2022, is expected to reach USD 11.15 billion by 2030, at a CAGR of 11.4% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Automated Nucleic Acid Extraction Devices Market Scope and Segmentation  

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Type (Instruments, Kits and Consumables), Product (Fully Automated, Semi-Automated), End User (Hospitals, Diagnostic Centers, Forensic Laboratories, Pharmaceutical and Biotechnology Companies, Academic Research Institutes)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

QIAGEN (Germany), F. Hoffmann-La Roche Ltd (U.S.), Analytik Jena GmbH+Co. KG (Germany), Thermo Fisher Scientific Inc. (U.S.), AccuBioMed Co., Ltd. (Taiwan), AUTOGEN INC. (U.S.), Bioneer Corporation (South Korea), Illumina, Inc. (U.S.), Tecan Trading AG (Switzerland), Merck KGaA (Germany), BD (U.S.), PerkinElmer, Inc. (U.S.), DiaSorin S.p.A (Italy)

Market Opportunities

  • Increasing demand for nucleic acid extraction from various sample types
  • Technological advancements in automated nucleic acid extraction systems

Market Definition

Automated devices significantly reduce the time and labour required to manually extract nucleic acids from the same number of samples. They also avoid the introduction of human error that can occur during manual extraction. The automated nucleic acid extraction devices are adaptable and efficient systems for fully automated nucleic acid isolation. They are based on a unique liquid handling method and the proven principle of magnetic particle separation or smart extraction, such as the GENE PREP STAR, which is an automated plasmid DNA extractor used by many clinical and research institutes.

Automated Nucleic Acid Extraction Devices Market Dynamics

Drivers

  • Increasing demand of new extraction techniques

Nucleic acid amplification has advanced at an unprecedented rate, resulting in increased sensitivity and specificity. However, to obtain satisfactory results when using this new technique, testing must go through several significant phases. Sample preparation and collection, specimen transportation and storage, sample stability, and nucleic acid extraction are all variables used in preanalytical testing. This increases the market's growth.

  • Growing number of research and development activities 

The extraction of nucleic acids is the first step in many research and therapeutic applications. Numerous nucleic acid samples must be extracted as a starting point for the implementation of high-throughput multiplex systems for genotyping, gene expression, and epigenetic profiling. The results of these methods have important implications for fundamental research as well as clinical diagnosis and follow-up. This contributes to market expansion.

Opportunities

  • Technological advancement in analytical instruments and laboratory automation

BioMérieux's NucliSens easy MAGTM is a user-friendly automated device designed for extracting high-quality RNA and DNA. The primary goals of the development were to improve the overall design, usability, and convenience of an automated platform, particularly when compared to previous-generation instruments, as well as to improve the performance of the underlying chemistry for nucleic acid extraction.

Restraints/Challenges

  • High cost

The high maintenance and service costs and the limited product acceptability will slow the market's growth rate. The lack of skilled professionals and a lack of healthcare infrastructure in developing economies will pose a challenge to the market for automated nucleic acid extraction devices.

This automated nucleic acid extraction devices market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the automated nucleic acid extraction devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Automated Nucleic Acid Extraction Devices Market

The COVID-19 outbreak had a positive effect on the market. Disease outbreaks such as SARS, MERS, swine flu, Ebola, and COVID-19 (current) have caused misery, fatalities, and financial losses around the world. Rapid point-of-care (POC) molecular detection of human and plant diseases is becoming increasingly important in order to control disease spread and protect human populations. Nucleic acid-based molecular diagnosis reveals disease-causing pathogens and their pathogenesis at the genomic level, which benefits patients, healthcare providers, and researchers by enabling more effective pathogen detection, disease progression tracking, and treatment planning.

Global Automated Nucleic Acid Extraction Devices Market Scope

The automated nucleic acid extraction devices market is segmented on the basis of product, type, end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Instruments
  • Kits
  • Consumables

 Product

  • Fully Automated
  • Semi-Automated

End User

  • Hospitals
  • Diagnostic Centers
  • Forensic Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Academic Research Institutes

Automated Nucleic Acid Extraction Devices Market Regional Analysis/Insights

The automated nucleic acid extraction devices market is analyzed and market size insights and trends are provided by country, product, type, end-user as referenced above.

The countries covered in the automated nucleic acid extraction devices market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the automated nucleic acid extraction devices market due to the adoption of stringent standards for analysis along with rapid technological advancement.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the availability of advanced laboratory equipment along with growing number of research and development activities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The automated nucleic acid extraction devices market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for automated nucleic acid extraction devices market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the automated nucleic acid extraction devices market. The data is available for historic period 2011-2021.

Competitive Landscape and Automated Nucleic Acid Extraction Devices Market Share Analysis

The automated nucleic acid extraction devices market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to automated nucleic acid extraction devices market.

Some of the major players operating in the automated nucleic acid extraction devices market are:

  • QIAGEN (Germany)
  • F. Hoffmann-La Roche Ltd (U.S.)
  • Analytik Jena GmbH+Co. KG (Germany)
  • Thermo Fisher Scientific Inc. (U.S.)
  • AccuBioMed Co., Ltd. (Taiwan)
  • AUTOGEN INC. (U.S.)
  • Bioneer Corporation (South Korea)
  • Illumina, Inc. (U.S.)
  • Tecan Trading AG (Switzerland)
  • Merck KGaA (Germany)
  • BD (U.S.)
  • PerkinElmer, Inc. (U.S.)
  • DiaSorin S.p.A (Italy)
  • Diagcor Bioscience Incorporation Limited (China)

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

5.1 PESTEL ANALYSIS

5.2 PORTER’S FIVE FORCES MODEL

6 INDUSTRY INSIGHTS

6.1 MICRO AND MACRO ECONOMIC FACTORS

6.2 PENETRATION AND GROWTH PROSPECT MAPPING

6.3 KEY PRICING STRATEGIES

6.4 INTERVIEWS WITH SPECIALIST

6.5 ANALYIS AND RECOMMENDATION

7 INTELLECTUAL PROPERTY (IP) PORTFOLIO

7.1 PATENT QUALITY AND STRENGTH

7.2 PATENT FAMILIES

7.3 LICENSING AND COLLABORATIONS

7.4 COMPETITIVE LANDSCAPE

7.5 IP STRATEGY AND MANAGEMENT

7.6 OTHER

8 COST ANALYSIS BREAKDOWN

9 TECHNONLOGY ROADMAP

10 INNOVATION TRACKER AND STRATEGIC ANALYSIS

10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS

10.1.1 JOINT VENTURES

10.1.2 MERGERS AND ACQUISITIONS

10.1.3 LICENSING AND PARTNERSHIP

10.1.4 TECHNOLOGY COLLABORATIONS

10.1.5 STRATEGIC DIVESTMENTS

10.2 NUMBER OF PRODUCTS IN DEVELOPMENT

10.3 STAGE OF DEVELOPMENT

10.4 TIMELINES AND MILESTONES

10.5 INNOVATION STRATEGIES AND METHODOLOGIES

10.6 RISK ASSESSMENT AND MITIGATION

10.7 FUTURE OUTLOOK

11 REGULATORY COMPLIANCE

11.1 REGULATORY AUTHORITIES

11.2 REGULATORY CLASSIFICATIONS

11.2.1 CLASS I

11.2.2 CLASS II

11.2.3 CLASS III

11.3 REGULATORY SUBMISSIONS

11.4 INTERNATIONAL HARMONIZATION

11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS

11.6 REGULATORY CHALLENGES AND STRATEGIES

12 REIMBURSEMENT FRAMEWORK

13 OPPUTUNITY MAP ANALYSIS

14 VALUE CHAIN ANALYSIS

15 HEALTHCARE ECONOMY

15.1 HEALTHCARE EXPENDITURE

15.2 CAPITAL EXPENDITURE

15.3 CAPEX TRENDS

15.4 CAPEX ALLOCATION

15.5 FUNDING SOURCES

15.6 INDUSTRY BENCHMARKS

15.7 GDP RATION IN OVERALL GDP

15.8 HEALTHCARE SYSTEM STRUCTURE

15.9 GOVERNMENT POLICIES

15.1 ECONOMIC DEVELOPMENT

16 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, BY PRODUCT TYPE

16.1 OVERVIEW

16.2 INSTRUMENTS

16.2.1 BY MODE

16.2.1.1. FULLY-AUTOMATED

16.2.1.2. SEMI-AUTOMATED

16.2.2 BY THROUGHPUT LEVEL

16.2.2.1. MEDIUM

16.2.2.2. HIGH

16.2.3 BY NUCLEIC ACID TYPE

16.2.3.1. RNA

16.2.3.2. DNA

16.2.3.3. HYBRID

16.2.4 BY MODALITY

16.2.4.1. BENCHTOP

16.2.4.2. STANDALONE

16.2.4.3. PORTABLE

16.2.5 BY SAMPLE VOLUME

16.2.5.1. 10~1000 µL

16.2.5.2. 1000~2000 µL

16.2.5.3. 0.2-1ML

16.2.5.4. OTHERS

16.3 KITS & CONSUMABLES

16.3.1 NUCLEIC ACID EXTRACTION KITS

16.3.1.1. BY TYPE

16.3.1.1.1. 48 T

16.3.1.1.2. 24 T

16.3.1.1.3. 96 T

16.3.1.1.4. OTHERS

16.3.1.2. BY CATEGORY

16.3.1.2.1. SINGLE TYPE EXTRACTION KIT

16.3.1.2.2. MULTI-TYPE EXTRACTION KIT

16.3.2 MAGNETIC BEADS

16.3.3 WELL PLATES

16.3.4 TIP COMBS SETS

16.3.5 BINDING COLUMNS

16.3.6 BUFFERS

16.3.7 SPIN COLUMNS

16.3.8 OTHERS

16.4 OTHERS

17 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, BY TECHNOLOGY

17.1 OVERVIEW

17.2 MAGNETIC BEADS TECHNOLOGY (MB)

17.3 ONE-TUBE FAST RELEASE TECHNOLOGY (OT)

17.4 PARTICLE MOVER TECHNOLOGY

17.5 OTHERS

18 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, BY SAMPLE TYPE

18.1 OVERVIEW

18.2 PLASMA

18.3 SERUM

18.4 WHOLE BLOOD

18.5 SALIVA

18.6 URINE

18.7 TISSUE

18.8 SECRETIONS

18.9 EXFOLIATED CELLS,

18.1 NASOPHARYNGEAL SWAB

18.11 OROPHARYNGEAL SWAB

18.12 FECES

18.13 OTHERS

19 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, BY APPLICATION

19.1 OVERVIEW

19.2 CLINICAL

19.2.1 SEXUALLY TRANSMITTED DISEASES

19.2.1.1. CHLAMYDIA

19.2.1.2. HSV-2

19.2.1.3. HSV I/2

19.2.1.4. OTHERS

19.2.2 WOMEN’S HEALTH

19.2.3 RESPIRATORY TRACT DISEASE

19.2.3.1. RESPIRATORY SYNCYTIAL VIRUS

19.2.3.2. TUBERCULOSIS

19.2.3.3. MYCOPLASMA PNEUMONIAE INFECTION

19.2.3.4. OTHERS

19.2.4 GASTROINTESTINAL DISEASES

19.2.5 PRENATAL AND POSTNATAL CARE

19.2.6 INFECTIOUS DISEASES

19.2.6.1. SARS-COV-2

19.2.6.2. INFLUENZA A/B

19.2.6.3. HINI

19.2.6.4. H7N9

19.2.6.5. OTHERS

19.3 RESEARCH

20 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, BY END USER

20.1 OVERVIEW

20.2 HOSPITALS

20.2.1 BY TYPE

20.2.1.1. PRIVATE

20.2.1.1.1. TIER 1

20.2.1.1.2. TIER 2

20.2.1.1.3. TIER 3

20.2.1.2. PUBLIC

20.2.1.2.1. TIER 1

20.2.1.2.2. TIER 2

20.2.1.2.3. TIER 3

20.3 DIAGNOSTIC CENTERS

20.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES

20.5 ACADEMIC AND RESEARCH ORGANIZATIONS

20.6 OTHERS

21 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, BY DISTRIBUTION CHANNEL

21.1 OVERVIEW

21.2 DIRECT TENDER

21.3 RETAIL SALES

21.4 OTHERS

22 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, SWOT AND DBMR ANALYSIS

23 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, COMPANY LANDSCAPE

23.1 COMPANY SHARE ANALYSIS: GLOBAL

23.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

23.3 COMPANY SHARE ANALYSIS: EUROPE

23.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

23.5 MERGERS & ACQUISITIONS

23.6 NEW PRODUCT DEVELOPMENT & APPROVALS

23.7 EXPANSIONS

23.8 REGULATORY CHANGES

23.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

24 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, BY REGION

GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

24.1 NORTH AMERICA

24.1.1 U.S.

24.1.2 CANADA

24.1.3 MEXICO

24.2 EUROPE

24.2.1 GERMANY

24.2.2 U.K.

24.2.3 ITALY

24.2.4 FRANCE

24.2.5 SPAIN

24.2.6 RUSSIA

24.2.7 SWITZERLAND

24.2.8 TURKEY

24.2.9 BELGIUM

24.2.10 NETHERLANDS

24.2.11 DENMARK

24.2.12 SWEDEN

24.2.13 POLAND

24.2.14 NORWAY

24.2.15 FINLAND

24.2.16 REST OF EUROPE

24.3 ASIA-PACIFIC

24.3.1 JAPAN

24.3.2 CHINA

24.3.3 SOUTH KOREA

24.3.4 INDIA

24.3.5 SINGAPORE

24.3.6 THAILAND

24.3.7 INDONESIA

24.3.8 MALAYSIA

24.3.9 PHILIPPINES

24.3.10 AUSTRALIA

24.3.11 NEW ZEALAND

24.3.12 VIETNAM

24.3.13 TAIWAN

24.3.14 REST OF ASIA-PACIFIC

24.4 SOUTH AMERICA

24.4.1 BRAZIL

24.4.2 ARGENTINA

24.4.3 REST OF SOUTH AMERICA

24.5 MIDDLE EAST AND AFRICA

24.5.1 SOUTH AFRICA

24.5.2 EGYPT

24.5.3 BAHRAIN

24.5.4 UNITED ARAB EMIRATES

24.5.5 KUWAIT

24.5.6 OMAN

24.5.7 QATAR

24.5.8 SAUDI ARABIA

24.5.9 REST OF MEA

24.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

25 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, COMPANY PROFILE

25.1 BIO-RAD LABORATORIES, INC.

25.1.1 COMPANY OVERVIEW

25.1.2 REVENUE ANALYSIS

25.1.3 GEOGRAPHIC PRESENCE

25.1.4 PRODUCT PORTFOLIO

25.1.5 RECENT DEVELOPMENTS

25.2 ESCO MICRO PTE. LTD.

25.2.1 COMPANY OVERVIEW

25.2.2 REVENUE ANALYSIS

25.2.3 GEOGRAPHIC PRESENCE

25.2.4 PRODUCT PORTFOLIO

25.2.5 RECENT DEVELOPMENTS

25.3 QIAGEN

25.3.1 COMPANY OVERVIEW

25.3.2 REVENUE ANALYSIS

25.3.3 GEOGRAPHIC PRESENCE

25.3.4 PRODUCT PORTFOLIO

25.3.5 RECENT DEVELOPMENTS

25.4 AUTOGEN INC.

25.4.1 COMPANY OVERVIEW

25.4.2 REVENUE ANALYSIS

25.4.3 GEOGRAPHIC PRESENCE

25.4.4 PRODUCT PORTFOLIO

25.4.5 RECENT DEVELOPMENTS

25.5 THERMO FISHER SCIENTIFIC INC.

25.5.1 COMPANY OVERVIEW

25.5.2 REVENUE ANALYSIS

25.5.3 GEOGRAPHIC PRESENCE

25.5.4 PRODUCT PORTFOLIO

25.5.5 RECENT DEVELOPMENTS

25.6 PERKINELMER INC.

25.6.1 COMPANY OVERVIEW

25.6.2 REVENUE ANALYSIS

25.6.3 GEOGRAPHIC PRESENCE

25.6.4 PRODUCT PORTFOLIO

25.6.5 RECENT DEVELOPMENTS

25.7 MP BIOMEDICALS

25.7.1 COMPANY OVERVIEW

25.7.2 REVENUE ANALYSIS

25.7.3 GEOGRAPHIC PRESENCE

25.7.4 PRODUCT PORTFOLIO

25.7.5 RECENT DEVELOPMENTS

25.8 GENEREACH BIOTECHNOLOGY CORP.

25.8.1 COMPANY OVERVIEW

25.8.2 REVENUE ANALYSIS

25.8.3 GEOGRAPHIC PRESENCE

25.8.4 PRODUCT PORTFOLIO

25.8.5 RECENT DEVELOPMENTS

25.9 PROMEGA CORPORATION

25.9.1 COMPANY OVERVIEW

25.9.2 REVENUE ANALYSIS

25.9.3 GEOGRAPHIC PRESENCE

25.9.4 PRODUCT PORTFOLIO

25.9.5 RECENT DEVELOPMENTS

25.1 HOFFMANN-LA ROCHE LTD

25.10.1 COMPANY OVERVIEW

25.10.2 REVENUE ANALYSIS

25.10.3 GEOGRAPHIC PRESENCE

25.10.4 PRODUCT PORTFOLIO

25.10.5 RECENT DEVELOPMENTS

25.11 ANALYTIK JENA GMBH+CO. KG

25.11.1 COMPANY OVERVIEW

25.11.2 REVENUE ANALYSIS

25.11.3 GEOGRAPHIC PRESENCE

25.11.4 PRODUCT PORTFOLIO

25.11.5 RECENT DEVELOPMENTS

25.12 ACCUBIOMED CO., LTD.

25.12.1 COMPANY OVERVIEW

25.12.2 REVENUE ANALYSIS

25.12.3 GEOGRAPHIC PRESENCE

25.12.4 PRODUCT PORTFOLIO

25.12.5 RECENT DEVELOPMENTS

25.13 BIONEER CORPORATION

25.13.1 COMPANY OVERVIEW

25.13.2 REVENUE ANALYSIS

25.13.3 GEOGRAPHIC PRESENCE

25.13.4 PRODUCT PORTFOLIO

25.13.5 RECENT DEVELOPMENTS

25.14 TECAN TRADING AG

25.14.1 COMPANY OVERVIEW

25.14.2 REVENUE ANALYSIS

25.14.3 GEOGRAPHIC PRESENCE

25.14.4 PRODUCT PORTFOLIO

25.14.5 RECENT DEVELOPMENTS

25.15 BD

25.15.1 COMPANY OVERVIEW

25.15.2 REVENUE ANALYSIS

25.15.3 GEOGRAPHIC PRESENCE

25.15.4 PRODUCT PORTFOLIO

25.15.5 RECENT DEVELOPMENTS

25.16 HAMILTON COMPANY

25.16.1 COMPANY OVERVIEW

25.16.2 REVENUE ANALYSIS

25.16.3 GEOGRAPHIC PRESENCE

25.16.4 PRODUCT PORTFOLIO

25.16.5 RECENT DEVELOPMENTS

25.17 AURORA BIOMED INC.

25.17.1 COMPANY OVERVIEW

25.17.2 REVENUE ANALYSIS

25.17.3 GEOGRAPHIC PRESENCE

25.17.4 PRODUCT PORTFOLIO

25.17.5 RECENT DEVELOPMENTS

25.18 JIANGSU BIOPERFECTUS TECHNOLOGIES CO., LTD

25.18.1 COMPANY OVERVIEW

25.18.2 REVENUE ANALYSIS

25.18.3 GEOGRAPHIC PRESENCE

25.18.4 PRODUCT PORTFOLIO

25.18.5 RECENT DEVELOPMENTS

25.19 ADS BIOTEC INC.

25.19.1 COMPANY OVERVIEW

25.19.2 REVENUE ANALYSIS

25.19.3 GEOGRAPHIC PRESENCE

25.19.4 PRODUCT PORTFOLIO

25.19.5 RECENT DEVELOPMENTS

25.2 SEEGENE INC.

25.20.1 COMPANY OVERVIEW

25.20.2 REVENUE ANALYSIS

25.20.3 GEOGRAPHIC PRESENCE

25.20.4 PRODUCT PORTFOLIO

25.20.5 RECENT DEVELOPMENTS

26 RELATED REPORTS

27 CONCLUSION

28 QUESTIONNAIRE

29 ABOUT DATA BRIDGE MARKET RESEARCH

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Automated Nucleic Acid Extraction Devices Market is projected to grow at a CAGR of 11.4% during the forecast period by 2030.
The future market value of the Automated Nucleic Acid Extraction Devices Market is expected to reach USD 11.15 billion by 2030.
The major players in the Automated Nucleic Acid Extraction Devices Market are QIAGEN (Germany), F. Hoffmann-La Roche Ltd (U.S.), Analytik Jena GmbH+Co. KG (Germany), Thermo Fisher Scientific Inc. (U.S.), AccuBioMed Co., Ltd. (Taiwan), AUTOGEN INC. (U.S.), etc.
The countries covered in the Automated Nucleic Acid Extraction Devices Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, etc.
Testimonial